Biolinerx Stock Performance
| BLRX Stock | USD 0.75 0.07 8.54% |
The firm shows a Beta (market volatility) of 1.15, which signifies a somewhat significant risk relative to the market. BioLineRx returns are very sensitive to returns on the market. As the market goes up or down, BioLineRx is expected to follow. BioLineRx has an expected return of -0.68%. Please make sure to confirm BioLineRx jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if BioLineRx performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BioLineRx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in July 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:15 | Dividend Date 2019-07-15 | Last Split Date 2019-07-15 |
1 | BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 - Yahoo Finance | 03/20/2024 |
2 | BLRX Stock Earnings BioLine Rx Beats EPS for Q4 2023 | 03/26/2024 |
3 | Equities Analysts Offer Predictions for BioLineRx Ltd.s Q1 2024 Earnings - Defense World | 03/28/2024 |
4 | Are BioLineRx weak basic indicators contributing to the current slide | 05/03/2024 |
5 | BLRX Stock Earnings BioLine Rx Beats EPS for Q1 2024 | 05/28/2024 |
6 | Analysts Issue Forecasts for BioLineRx Ltd.s Q2 2024 Earnings - MarketBeat | 05/31/2024 |
| Begin Period Cash Flow | 10.6 M |
BioLineRx |
BioLineRx Relative Risk vs. Return Landscape
If you would invest 133.00 in BioLineRx on March 5, 2024 and sell it today you would lose (58.00) from holding BioLineRx or give up 43.61% of portfolio value over 90 days. BioLineRx is currently does not generate positive expected returns and assumes 6.6109% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than BioLineRx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioLineRx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioLineRx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioLineRx, and traders can use it to determine the average amount a BioLineRx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1033
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BLRX |
Estimated Market Risk
| 6.61 actual daily | 58 58% of assets are less volatile |
Expected Return
| -0.68 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioLineRx is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioLineRx by adding BioLineRx to a well-diversified portfolio.
BioLineRx Fundamentals Growth
BioLineRx Stock prices reflect investors' perceptions of the future prospects and financial health of BioLineRx, and BioLineRx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioLineRx Stock performance.
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (2.47) % | ||||
| Current Valuation | 749.85 M | ||||
| Shares Outstanding | 79.94 M | ||||
| Price To Earning | (3.88) X | ||||
| Price To Book | 4.33 X | ||||
| Price To Sales | 11.94 X | ||||
| Revenue | 4.8 M | ||||
| EBITDA | (41.61 M) | ||||
| Net Income | (60.61 M) | ||||
| Cash And Equivalents | 43.15 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 11.59 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (22.61 M) | ||||
| Earnings Per Share | (0.76) X | ||||
| Market Capitalization | 59.6 M | ||||
| Total Asset | 63.92 M | ||||
| Retained Earnings | (390.61 M) | ||||
| Working Capital | 16.33 M | ||||
| Current Asset | 48.18 M | ||||
| Current Liabilities | 3.14 M | ||||
About BioLineRx Performance
To evaluate BioLineRx Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when BioLineRx generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare BioLineRx Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand BioLineRx market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents BioLineRx's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 154.10 | 161.80 | |
| Return On Tangible Assets | (1.24) | (1.30) | |
| Return On Capital Employed | (1.30) | (1.23) | |
| Return On Assets | (0.95) | (0.90) | |
| Return On Equity | (4.58) | (4.35) |
Things to note about BioLineRx performance evaluation
Checking the ongoing alerts about BioLineRx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioLineRx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioLineRx generated a negative expected return over the last 90 days | |
| BioLineRx has high historical volatility and very poor performance | |
| BioLineRx has some characteristics of a very speculative penny stock | |
| BioLineRx has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.8 M. Net Loss for the year was (60.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLineRx currently holds about 43.15 M in cash with (22.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BioLineRx has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Analysts Issue Forecasts for BioLineRx Ltd.s Q2 2024 Earnings - MarketBeat |
- Analyzing BioLineRx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioLineRx's stock is overvalued or undervalued compared to its peers.
- Examining BioLineRx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioLineRx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioLineRx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioLineRx's stock. These opinions can provide insight into BioLineRx's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for BioLineRx Stock analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Stocks Directory Find actively traded stocks across global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is BioLineRx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioLineRx. If investors know BioLineRx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioLineRx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.76) | Revenue Per Share 0.075 | Return On Assets (0.38) | Return On Equity (1.89) |
The market value of BioLineRx is measured differently than its book value, which is the value of BioLineRx that is recorded on the company's balance sheet. Investors also form their own opinion of BioLineRx's value that differs from its market value or its book value, called intrinsic value, which is BioLineRx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioLineRx's market value can be influenced by many factors that don't directly affect BioLineRx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioLineRx's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLineRx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLineRx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.